Blueprint
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
 
 
For period ending 8 February 2019
 
GlaxoSmithKline plc
(Name of registrant)
 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 
 
Form 20-F x     Form 40-F
 
--
 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
 
 
 GlaxoSmithKline plc (the 'Company')
Transaction notification
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
Nature of thetransaction
The exercise of options over 4,600 ADSs, granted on 17 February 2009 under the GlaxoSmithKline Share Option Plan.
c)
Price(s) and volume(s)
 Price(s)
Volume(s)
$33.4200
1,608 (Non-Qualified Stock Option)
$33.4200
2,992 (Incentive Stock Option)
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
4,600$33.4200
e)
Date of thetransaction
2019-02-07
f)
Place of the transaction
 
n/a
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
Nature of thetransaction
The sale of 4,600 ADSs, following the exercise of options granted on 17 February 2009 under the GlaxoSmithKline Share Option Plan.
 
c)
Price(s) and volume(s)
 Price(s)
Volume(s)
$41.0800
1,608 (Non-Qualified Stock Option)
$41.0800
2,992 (Incentive Stock Option)
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
4,600$41.0800
e)
Date of thetransaction
2019-02-07
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 08, 2019 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc